HPV相关口咽癌治疗后早期循环肿瘤组织修饰病毒HPV DNA检测的价值
本研究回顾性分析332例活检证实的HPV相关口咽鳞状细胞癌患者,在初始根治性治疗后1-89天进行至少一次TTMV-HPV DNA检测,采用90天界标法评估无事件生存。首次检测阴性310例(93%),不确定3例(1%),阳性19例(6%);持续阳性者复发风险增加,而阳性转阴者未出现复发。
要点
- 治疗后1-89天TTMV-HPV DNA检测结果与后续无事件生存相关
- 持续阳性提示复发风险增加,阳性转阴者本队列未复发
- 早期检测可能辅助常规3个月疗效评估前的风险分层
核心结论
- 在HPV相关口咽鳞状细胞癌治疗后1-89天进行TTMV-HPV DNA检测与后续临床结局相关。
- 持续阳性识别出复发风险增加的患者,而阳性转阴者在本队列中未出现复发。
研究设计与样本
- 回顾性分析美国8个中心的332例活检证实的HPV相关口咽鳞状细胞癌患者。
- 患者接受初始根治性治疗,并在治疗完成后1至89天进行至少一次TTMV-HPV DNA检测。
- 采用90天界标法评估无事件生存(EFS)。
主要发现
- 首次检测(治疗后1-89天)阴性310例(93%),不确定3例(1%),阳性19例(6%)。
- 59例初始阴性后重复检测者中,57例(97%)保持阴性,2例(3%)转为阳性,且这两例后续均出现复发。
- 13例初始阳性且有足够随访分析轨迹者中,6例(46%)转为阴性且均未复发,7例(54%)持续阳性且其中6例(86%)出现复发。
- 在90天界标分析中,治疗后早期最后一次TTMV-HPV DNA结果与后续无事件生存相关。
临床怎么用
- 对于HPV相关口咽鳞状细胞癌根治性治疗后患者,可考虑在1-89天进行TTMV-HPV DNA检测以辅助风险分层。
- 检测持续阳性者需警惕复发风险增加,阳性转阴者复发风险可能较低。
局限性
- 回顾性研究设计。
- 轨迹分析仅纳入13例初始阳性且有足够随访的患者,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TTMV-HPV DNA testing is prognostic during post-treatment surveillance of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but the significance of testing before conventional 3-month response assessment remains unclear. METHODS: We retrospectively analyzed 332 patients across 8 US sites with biopsy-proven HPV-associated OPSCC who underwent initial definitive treatment and had ≥ 1 TTMV-HPV DNA test performed 1 to 89 days after treatment completion. Event-free survival (EFS) was evaluated using a 90-day landmark approach. RESULTS: The first TTMV-HPV DNA test obtained 1-89 days after treatment was negative in 310 patients (93%), indeterminate in 3 (1%), and positive in 19 (6%). Among 59 patients with repeat testing after an initially negative result, 57 (97%) remained negative and 2 (3%) converted to positive; both patients who converted subsequently developed recurrence. Of 13 patients with an initially positive result and sufficient follow-up for trajectory analysis, 6 (46%) subsequently resolved to negative and none developed recurrence, whereas 7 (54%) remained persistently positive and 6 (86%) developed recurrence. In a 90-day landmark analysis, the last early post-treatment TTMV-HV DNA result was associated with subsequent event-free survival. CONCLUSIONS: TTMV-HPV DNA testing during the 1-89-day post-treatment interval was associated with subsequent clinical outcomes in HPV-associated OPSCC. Persistent positivity identified patients at increased risk, whereas positive results that resolved were not followed by recurrence in this cohort.
引用
- Roof SA, Jabalee J, Rettig EM, et al. Utility of Early Post-Treatment Circulating Tumor Tissue Modified Viral HPV DNA Testing in HPV-Associated Oropharyngeal Cancer. Head Neck. 2026. PMID: 42844772. doi:10.1002/hed.70483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。